1. Home
  2. NVCT vs EVO Comparison

NVCT vs EVO Comparison

Compare NVCT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvectis Pharma Inc.

NVCT

Nuvectis Pharma Inc.

HOLD

Current Price

$21.07

Market Cap

617.7M

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.54

Market Cap

568.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVCT
EVO
Founded
2020
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
617.7M
568.6M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
NVCT
EVO
Price
$21.07
$1.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$7.00
AVG Volume (30 Days)
168.1K
138.4K
Earning Date
05-06-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.55
$1.50
52 Week High
$29.28
$4.27

Technical Indicators

Market Signals
Indicator
NVCT
EVO
Relative Strength Index (RSI) 48.82 N/A
Support Level $17.98 N/A
Resistance Level $23.12 N/A
Average True Range (ATR) 1.47 0.00
MACD -0.26 0.00
Stochastic Oscillator 41.23 0.00

Price Performance

Historical Comparison
NVCT
EVO

About NVCT Nuvectis Pharma Inc.

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: